• Investors
  • News
  • Subscribe
Hit enter to search or ESC to close
Cardax, Inc. | CDXI
  • About Us
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Company History
  • Astaxanthin
    • Overview
      • Astaxanthin Overview
      • History and Background
      • Safety
      • Mechanism of Action
      • Synthetic vs. Natural Astaxanthin
    • Research in Key Addressable Markets
      • Cardiovascular Disease
      • Metabolic Disease
      • Liver Disease
      • Arthritis
      • Aging
      • Coronavirus Disease 2019 (COVID-19)
    • Scientific Literature
  • Programs
    • Product Platform
    • Commercialization Strategy
    • ZanthoSyn®
    • CDX-101
    • CDX-301
    • CHASE Clinical Trial
    • Intellectual Property
  • Newsroom
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
Cardax, Inc. | CDXI

Press Releases

Investor Relations
Investors
  • Overview
  • News / Events
    • Press Releases
    • Media Coverage
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Profile
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

Cardax and GNC Announce Expanded ZanthoSyn® Sales and Marketing Program

Dec 3, 2018

Cardax Names Former Amarin Head of Development Paresh N. Soni, MD, PhD, to lead Clinical and Regulatory Strategy

Nov 28, 2018

Cardax Reports Q3 2018 Results

Nov 13, 2018

Cardax Launches Human Clinical Trial Targeting Cardiovascular Inflammatory Health

Oct 2, 2018

Cardax Reports Q2 2018 Results

Aug 13, 2018

Cardax Announces Successful Completion of Warrant Exchange Offer

Jul 30, 2018

Cardax Announces Extension of Warrant Exchange Offer to July 27, 2018

Jul 23, 2018

Cardax Announces Effectiveness of Registration Statement and Commencement of Warrant Exchange Offer

Jun 22, 2018

Cardax Engages Industry Veteran Fred Sancilio, Ph.D., to Launch Orphan Drug Development Program

Jun 13, 2018

Cardax Adds Makarand Jawadekar, Ph.D., and Elona Kogan to its Board of Directors

Jun 1, 2018
RSS
  • 1
  • 2

News / Events

  • Press Releases
  • Media Coverage
  • IR Calendar
  • Presentations
  • Email Alerts
Subscribe to Receive Updates by E-Mail Cardax News Alerts

Recent News

  • Cardax Announces Breakthrough Longevity Results with ZanthoSyn® in NIH-Funded StudyDecember 6, 2023
  • Cardax Refocuses on ZanthoSyn® Consumer Health BusinessAugust 31, 2021
  • Cardax Voluntarily Suspends SEC Reporting ObligationsAugust 11, 2021

*These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.

© 2025 Cardax, Inc. | Disclaimer and Terms of Use | Accessibility Statement

  • About Us
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Company History
  • Astaxanthin
    • Overview
      • Astaxanthin Overview
      • History and Background
      • Safety
      • Mechanism of Action
      • Synthetic vs. Natural Astaxanthin
    • Research in Key Addressable Markets
    • Scientific Literature
  • Programs
    • Product Platform
    • Commercialization Strategy
    • ZanthoSyn®
    • CDX-101
    • CDX-301
    • CHASE Clinical Trial
    • Intellectual Property
  • Newsroom
  • Investors
    • Investor Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • Contact Us
  • Investors
  • News
  • Subscribe